BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018;9:11631-11637. [PMID: 29545925 DOI: 10.18632/oncotarget.24391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Cacciato V, Casagrande E, Bodini G, Furnari M, Marabotto E, Grillo F, Giannini EG. Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. Ann Hepatol. 2020;19:222-225. [PMID: 32029393 DOI: 10.1016/j.aohep.2019.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
2 Covini G, Bredi E, Badalamenti S, Roncalli M, Aghemo A, Colombo M. Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report. Hepatol Commun 2018;2:1179-83. [PMID: 30288473 DOI: 10.1002/hep4.1248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Putra J, Schiano TD, Fiel MI. Resolution of HCV-Autoimmune Hepatitis Overlap Syndrome With Antiviral TreatmentA Paired Liver Biopsy Study. Am J Clin Pathol 2019;152:735-41. [PMID: 31310654 DOI: 10.1093/ajcp/aqz095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Takakusagi S, Takagi H, Yokoyama Y, Marubashi K, Kizawa K, Kosone T, Sato K, Kakizaki S, Uraoka T. Successful treatment with glecaprevir/pibrentasvir for chronic hepatitis C complicated by primary biliary cholangitis. Clin J Gastroenterol 2020;13:896-901. [PMID: 32065362 DOI: 10.1007/s12328-020-01103-w] [Reference Citation Analysis]
5 Marincu I, Bratosin F, Curescu M, Suciu O, Turaiche M, Cerbu B, Vidican I. Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania. Medicina (Kaunas) 2021;57:986. [PMID: 34577909 DOI: 10.3390/medicina57090986] [Reference Citation Analysis]
6 Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Zhang X, Jain D. The many faces and pathologic diagnostic challenges of autoimmune hepatitis. Hum Pathol 2022:S0046-8177(22)00164-2. [PMID: 35753409 DOI: 10.1016/j.humpath.2022.06.019] [Reference Citation Analysis]
8 Sato K, Yamazaki Y, Kobayashi T, Takakusagi S, Horiguchi N, Kakizaki S, Andou M, Matsuda Y, Uraoka T, Ohnishi H, Okamoto H. Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature. World J Clin Cases 2019; 7(9): 1043-1052 [PMID: 31123677 DOI: 10.12998/wjcc.v7.i9.1043] [Reference Citation Analysis]
9 Kanda T, Matsuoka S, Moriyama M. Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response. Hepatol Int. 2018;12:90-93. [PMID: 29619621 DOI: 10.1007/s12072-018-9862-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]